

## Sector View

## Software and IT Services

## Accenture Q3 FY16 results: neutral read-across for European IT Services companies

	1 M	3 M	6 M	31/12/15
Softw.& Comp.	0.8%	0.1%	-0.9%	-3.2%
DJ Stoxx 600	1.0%	0.3%	-4.4%	-6.7%

\*Stoxx Sector Indices

## Companies covered

<b>ALTEN</b>	SELL	EUR48
Last Price	EUR54,69	Market Cap. EUR1,841m
<b>ALTRAN TECHNOLOGIES</b>	NEUTRAL	EUR13
Last Price	EUR12,585	Market Cap. EUR2,212m
<b>ATOS</b>	BUY	EUR93
Last Price	EUR81,84	Market Cap. EUR8,492m
<b>AXWAY SOFTWARE</b>	NEUTRAL	EUR20
Last Price	EUR20,7	Market Cap. EUR431m
<b>CAPGEMINI</b>	BUY	EUR97
Last Price	EUR86,97	Market Cap. EUR14,975m
<b>CAST</b>	NEUTRAL	EUR3,6
Last Price	EUR3,35	Market Cap. EUR54m
<b>DASSAULT SYSTEMES</b>	SELL	EUR63
Last Price	EUR69,15	Market Cap. EUR17,769m
<b>INDRA SISTEMAS</b>	NEUTRAL	EUR10
Last Price	EUR9,783	Market Cap. EUR1,606m
<b>SAGE GROUP</b>	SELL	555p
Last Price	623,5p	Market Cap. GBP6,730m
<b>SAP</b>	NEUTRAL	EUR73
Last Price	EUR70,09	Market Cap. EUR86,106m
<b>SOFTWARE AG</b>	BUY	EUR40
Last Price	EUR31,92	Market Cap. EUR2,522m
<b>SOPRA STERIA GROUP</b>	BUY	EUR130
Last Price	EUR112,05	Market Cap. EUR2,291m
<b>SWORD GROUP</b>	BUY	EUR26
Last Price	EUR24,7	Market Cap. EUR233m
<b>TEMENOS GROUP</b>	NEUTRAL	CHF52
Last Price	CHF55,05	Market Cap. CHF3,827m

Yesterday Accenture reported Q3 FY16 sales above consensus and EPS in line, while FY16 guidance has been fine-tuned slightly upwards for sales growth and EPS in order to reflect this quarter. Consulting has continued to enjoy strong momentum so far given healthy demand for digital transformation, at the expense of long-term Outsourcing contracts. In our view, this publication, which contains no major surprises, generates no significant catalysts for Capgemini and Atos.

## ANALYSIS

- Q3 FY16 sales above consensus and EPS in line.** For its Q3 FY16 (ending 31st May), Accenture has reported sales of USD8.43bn (+10% at cc or est. +8% lfl, vs. +12% at cc in Q2 FY16), slightly above the top-end of guidance (+7-10% at cc to USD8.1-8.35bn) and 2% ahead of the consensus figure (USD8.29bn), and diluted EPS up 8% to USD1.41 (consensus: USD1.41). Consulting was up 14% cc to USD4.62bn (vs. +18% in Q2 FY16), while Outsourcing was up 6% cc to USD3.81bn (vs. +6%). Consulting/Strategy showed a strong double-digit increase, Applications high single-digit, and Operations double-digit growth. Meanwhile, the Digital business (40% of sales) was up strong double-digit. North America was up 11% at cc (vs. +12%) with the eighth quarter of double-digit growth in the US, Europe was up 12% at cc (vs. +14%) with double-digit growth in the UK, Switzerland, Spain, Italy, Germany and France, and Growth Markets were up 6% at cc (vs. +10%) with double-digit growth in Japan and strong double-digit growth in China, India and Mexico, and modest growth in Brazil despite the current environment. By industry, the best performers were Products (+16%), and Financial Services and Health & Public Services (+12%). New bookings were up 7% to USD9.12bn (3% above consensus) or a book-to-bill of 1.08x (+9% in Consulting to USD4.93bn - book-to-bill 1.07x -, and +4% in Outsourcing to USD4.19bn - book-to-bill 1.10x).
- FY16 guidance fine-tuned.** For FY16, sales are now expected to rise 9.5-10.5% at cc (vs. +8%/+10% at cc previously) (consensus: +9.8% at cc), while the company has fine-tuned its guidance to 14.6% from 14.6-14.7% for operating margin and to USD5.29-5.33 from USD5.21-5.32 for EPS (excl. gains from the sale of Navitaire), vs. consensus at USD5.32. Consulting continues to enjoy strong momentum, led by the ongoing shift in corporate IT spending priorities to the "new" at the expense of optimising the existing. For Q4 FY16 (August 2016), Accenture projects sales of USD8.25-8.5bn (+6%/+9% at cc) or in line with consensus (USD8.34bn or +7.1% at cc), Finally, Accenture's global delivery network now accounts for 74% of staff (+3ppt), with GDN (global delivery network) headcount up 17% (vs. flat for onshore).
- Neutral read-across for European IT Services companies.** As there is fundamentally no surprise in these results, we consider the publication neutral for Capgemini and Atos in the short term. It indicates that digital transformation remains the key growth driver, and Accenture's investments in Digital, Cloud and Security have been the best way to gain market share so far. We consider that Capgemini is following the same path and that Atos has been catching up since 2014 - we forecast 3.8% lfl sales growth for Capgemini and +1.3% for Atos in 2016. Accenture's management has not seen any sign of slowdown in digital transformation so far: the latter is a structural move which will fade out when companies will end their transformation programmes - although we may fear that "Brexit" could call some IT investments into question. The next stage of digital transformation is trending towards the Internet of Things, artificial intelligence, virtual agents, etc., and Accenture, Capgemini and Atos are investing in these areas - internally as well.

## VALUATION

European IT Services companies: EV/EBIT multiples of 11.3x for 2016e and 9.4x for 2017e.

## NEXT CATALYSTS

TCS' Q1 FY17 results on 14th July. IBM's Q2 16 results on 18th July after US markets close.

[Click here to download document](#)



**Analyst :**  
 Gregory Ramirez  
 33(0) 1 56 68 75 91  
[gramirez@bryangarnier.com](mailto:gramirez@bryangarnier.com)

**Sector Team :**  
 Richard-Maxime Beaudoux  
 Thomas Coudry  
 Dorian Terral

# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

## Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

## Distribution of stock ratings

BUY ratings 56,5%

NEUTRAL ratings 34%

SELL ratings 9,5%

# Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

<b>London</b>	<b>Paris</b>	<b>New York</b>	<b>Munich</b>	<b>New Delhi</b>
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich	New Delhi 110 001
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	Tel +91 11 4132 6062
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	+91 98 1111 5119
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Fax +91 11 2621 9062
Authorised and regulated by the	Financial Conduct Authority (FCA) and the			<b>Geneva</b>
Financial Conduct Authority (FCA)	Autorité de Contrôle prudentiel et de			rue de Grenus 7
	resolution (ACPR)			CP 2113
				Genève 1, CH 1211
				Tel +4122 731 3263
				Fax+4122731 3243
				Regulated by the FINMA

#### **Important information**

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.